Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$94.96
-0.9%
$89.10
$81.97
$137.49
$165.14B0.6112.16 million shs6,361 shs
DexCom, Inc. stock logo
DXCM
DexCom
$73.04
-0.7%
$68.74
$54.11
$89.98
$28.14B1.455.29 million shs3,985 shs
Medtronic PLC stock logo
MDT
Medtronic
$82.74
-1.3%
$79.03
$73.31
$106.33
$105.83B0.569.32 million shs2,552 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.17%+5.64%+5.04%-7.62%-28.31%
DexCom, Inc. stock logo
DXCM
DexCom
+1.64%+9.24%+0.97%+11.81%-11.30%
Medtronic PLC stock logo
MDT
Medtronic
+0.82%+7.06%+2.59%-5.50%-4.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$94.96
-0.9%
$89.10
$81.97
$137.49
$165.14B0.6112.16 million shs6,361 shs
DexCom, Inc. stock logo
DXCM
DexCom
$73.04
-0.7%
$68.74
$54.11
$89.98
$28.14B1.455.29 million shs3,985 shs
Medtronic PLC stock logo
MDT
Medtronic
$82.74
-1.3%
$79.03
$73.31
$106.33
$105.83B0.569.32 million shs2,552 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.17%+5.64%+5.04%-7.62%-28.31%
DexCom, Inc. stock logo
DXCM
DexCom
+1.64%+9.24%+0.97%+11.81%-11.30%
Medtronic PLC stock logo
MDT
Medtronic
+0.82%+7.06%+2.59%-5.50%-4.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.89
Moderate Buy$118.4224.71% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$84.8816.21% Upside
Medtronic PLC stock logo
MDT
Medtronic
2.63
Moderate Buy$98.9619.60% Upside

Current Analyst Ratings Breakdown

Latest DXCM, ABT, and MDT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/6/2026
Medtronic PLC stock logo
MDT
Medtronic
Set Price Target$105.00
7/1/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Initiated CoverageOutperform$121.00
6/30/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
UpgradeStrong-Buy
6/23/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy
6/23/2026
DexCom, Inc. stock logo
DXCM
DexCom
Initiated CoverageBuy$86.00
6/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Reiterated RatingOverweight$115.00
6/17/2026
Medtronic PLC stock logo
MDT
Medtronic
Reiterated RatingBuy$101.00
6/16/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
DowngradeHold (C-)Sell (D+)
6/16/2026
Medtronic PLC stock logo
MDT
Medtronic
Reiterated RatingNeutral$85.00
6/15/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingOverweight$75.00 ➝ $88.00
6/12/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Lower Price Target$120.00 ➝ $102.00
(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$44.33B3.73$6.94 per share13.68$30.35 per share3.13
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.05$2.79 per share26.14$7.04 per share10.38
Medtronic PLC stock logo
MDT
Medtronic
$36.36B2.91$7.82 per share10.58$39.00 per share2.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.5726.5615.701.6513.90%17.62%10.01%7/16/2026 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3431.1723.951.1919.31%33.33%13.19%7/29/2026 (Estimated)
Medtronic PLC stock logo
MDT
Medtronic
$4.80B$3.7322.1612.972.2313.20%14.51%7.76%8/18/2026 (Estimated)

Latest DXCM, ABT, and MDT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.61N/AN/AN/A$1.29 billionN/A
7/16/2026Q2 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.28N/AN/AN/A$12.52 billionN/A
6/3/2026Q4 2026
Medtronic PLC stock logo
MDT
Medtronic
$1.54$1.55+$0.01$0.96$9.62 billion$9.81 billion
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
4/16/2026Q1 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.14$1.15+$0.01$0.61$10.99 billion$11.16 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.63%+10.39%70.59%54 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Medtronic PLC stock logo
MDT
Medtronic
$2.883.44%+4.13%77.21%49 Years

Latest DXCM, ABT, and MDT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/12/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.87%7/15/20267/15/20268/17/2026
6/3/2026
Medtronic PLC stock logo
MDT
Medtronic
quarterly$0.723.56%6/26/20266/26/20267/17/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.56
1.39
1.01
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Medtronic PLC stock logo
MDT
Medtronic
0.52
2.13
1.62

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Medtronic PLC stock logo
MDT
Medtronic
82.06%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Medtronic PLC stock logo
MDT
Medtronic
0.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Medtronic PLC stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable

Recent News About These Companies

Why Did Medtronic (NYSE:MDT) Report Strong Q4 Revenue Growth?
Top 10 medtech deals in the first half of 2026
J&J's MedTech Segment Eyes Another Strong Quarter in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$94.96 -0.88 (-0.92%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$73.04 -0.53 (-0.72%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Medtronic stock logo

Medtronic NYSE:MDT

$82.74 -1.09 (-1.30%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.